Targanta Therapeutics to Present at September 2008 Investor Conferences

  
    
  
  
    
      Targanta Therapeutics Corporation (Nasdaq: TARG) today announced its 
      planned participation in the following investor conferences in September 
      2008:
    
    
      
        BioCentury and Thomson Reuters Newsmakers in the Biotech Industry 
        Conference on Thursday, September 4, 2008 at 3:00 p.m. ET at the 
        Millennium Broadway Hotel & Conference Center in New York, NY.
      
      
        Thomas Weisel Partners Healthcare Conference on Friday, September 5, 
        2008 at 8:35 a.m. ET in the Stewart Room of the Four Seasons Hotel in 
        Boston, MA.
      
    
    
      Mark Leuchtenberger, President and Chief Executive Officer of Targanta, 
      will be presenting at both conferences. The presentations will be 
      webcast live and will be available for replay for approximately 30 days 
      following the presentations through the Investor Relations section of 
      Targanta’s website at www.targanta.com/investors.
    
    
      About Targanta Therapeutics
    
    
      Targanta Therapeutics Corporation (Nasdaq: TARG) is a biopharmaceutical 
      company focused on developing and commercializing innovative antibiotics 
      to treat serious infections in the hospital and other institutional 
      settings. The Company’s pipeline includes an 
      intravenous version of oritavancin, a semi-synthetic lipoglycopeptide 
      antibiotic currently awaiting U.S. and EU regulatory approval, and, a 
      program to develop an oral version of oritavancin for the treatment of Clostridium 
      difficile. The Company has operations in Cambridge, MA, 
      Indianapolis, IN, and Montreal, Québec, 
      Canada. For more information on Targanta, visit www.targanta.com.